API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The in vitro study, using Vero cells, found that “prophylactic oleandrin (as either the pure compound or as the active principal ingredient in PBI-06150) administration at concentrations as low as 0.05 μg/ml exhibited potent antiviral activity against SARS-CoV-2.
Lead Product(s): Oleandrin
Therapeutic Area: Infections and Infectious Diseases Product Name: PBI-06150
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2021
Details:
Published reports from in vitro cell culture studies have shown that oleandrin and extracts containing this molecule are effective against HIV, the Ebola virus as well as HTLV-1 and other viruses that are harmful to human health and well-being.
Lead Product(s): Oleandrin
Therapeutic Area: Infections and Infectious Diseases Product Name: PBI-05204
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020